UNSPSC 51452901: Malathion topical antiparasitic

This classification denotes a pediculocide with the molecular formula C10H19O6PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U5N7SU872W, chemically known as 1, 2-di(ethoxycarbonyl)ethyl o,o-dimethyl phosphordithioates but generally known as malathion, which bears US NIH Compound Identifier 4004. European Medicines Agency schedules Malathion in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14453MIG.

World Health Organization schedules malathion in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule malathion topical antiparasitic under HS 29309000 and SITC 51549. SMILES: CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC.

UNSPSC 51452901 Malathion topical antiparasitic, a Commodity code, shows a significant mismatch between its nominal scope and actual recent state and local procurement activity. The code appears designed for topical antiparasitic agents, yet the recent opportunities tagged under it encompass naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products. None of these solicitations involve malathion or topical antiparasitic treatments. The work actually being bought under this code classification spans emergency pharmaceutical supplies, pharmacy benefit management infrastructure, fire-rescue medical consumables, and pharmaceutical distribution networks—a portfolio entirely disconnected from the code's stated product line.

The issuing bodies include county governments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local jurisdictions). Geographic activity appears concentrated in Florida, Texas, and Minnesota, with the MMCAP procurement extending to Oregon and broader multistate participation. Representative recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems (due July 26, 2023, covering 1,900 units annually), the Texas HHS Commission's RFI HHS0017013 for therapeutic pharmacy initiative direct-to-manufacturer prescriptions (due April 3, 2026), the City of Tampa's IFB 26P00145 for medical and first aid supplies for the Fire Department Rescue Division (due March 13, 2026, estimated contract value $700,000.00 with SLBE set-aside), and the Minnesota MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, effective July 1, 2026). The code shows limited relevance to malathion antiparasitic procurement and should be evaluated for recoding accuracy before business development investment.